Only 57.3% of patients in the CagriSema trial reached the highest dose, with Novo providing no explanation for the low figure. A trial participant lost 18% of her weight but reported severe side ...

LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema ...

Novo Nordisk is “well placed” to continue to benefit from the high demand for GLP-1 medications in the near-term, and while the CagriSema Phase 3 data in obesity was disappointing, it is still ...